HRP20100469T1 - 3- ili 4-monosupstituirani fenolski i tiofenolski derivati, korisni kao h<sub>3</sub> ligandi - Google Patents

3- ili 4-monosupstituirani fenolski i tiofenolski derivati, korisni kao h<sub>3</sub> ligandi Download PDF

Info

Publication number
HRP20100469T1
HRP20100469T1 HR20100469T HRP20100469T HRP20100469T1 HR P20100469 T1 HRP20100469 T1 HR P20100469T1 HR 20100469 T HR20100469 T HR 20100469T HR P20100469 T HRP20100469 T HR P20100469T HR P20100469 T1 HRP20100469 T1 HR P20100469T1
Authority
HR
Croatia
Prior art keywords
alkyl
formula
optionally substituted
compound
phenyl
Prior art date
Application number
HR20100469T
Other languages
English (en)
Inventor
Bernardelli P.
Cronin A.M.
Denis A.
Denton S.M.
Jacobelli H.
Kemp M.I.
Lorthiois E.
Rousseau F.
Serradeil-Civit D.
Vergne F.
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04291187A external-priority patent/EP1593679A1/en
Priority claimed from GB0504564A external-priority patent/GB0504564D0/en
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of HRP20100469T1 publication Critical patent/HRP20100469T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Spoj formule (1): ili njegova farmaceutski prihvatljiva sol i/ili solvat (uključujući hidrat), naznačen time što: supstituent formule -Z-R je u meta- ili para-položaju na fenilnoj skupini; X se bira između -CN, -CH2OH, -CH2-O-(C1-C4)alkila, -C(O)OH, -C(O)O(C1-C4)alkil, -CH2-NR1R2, -C(O)NR3R4, -CH2-O-het2, -CH2-het1 i het1, gdje skupina het1 u i -CH2-het1 i het1 je izborno supstituirana s jednim ili dva supstituenta, koje se neovisno bira između halogena, cijano, (C1-C4)alkila, -S-(C1-C4)alkila i (C1-C4)alkoksi; R1 je vodik ili (C1-C4)alkil, izborno supstituiran s (C3-C8)cikloalkilom; R2 se bira iz skupine koju čine: vodik, (C1-C6)alkil, izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između (C3-C6)cikloalkila, hidroksi, -S-(C1-C4)alkila, -O-(C1-C4)alkila, -SO2(C1-C4)alkila, -SO-(C1-C4)alkila, halogena, het1, amino, (C1-C4)alkilamino, [(C1-C4)alkil]2amino i fenila, gdje navedeni fenil je izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, hidroksi, cijano, (C1-C4)alkila, (C1-C4)alkoksi i (C3-C6)cikloalkila, het2, izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, cijano, (C1-C4)alkila, NH2 i (C1-C4)alkoksi, -SO2-R5, gdje R5 se bira iz skupine koju čine (C1-C4)alkil, amino, (C1-C4)alkilamino, [(C1-C4)alkil]2amino, fenil i -(C1-C4)alkil-fenil, gdje navedeni fenil je izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, cijano, (C1-C4)alkila i (C1-C4)alkoksi, i-C(O)-R6, gdje R6 se bira iz skupine koju čine (C1-C4)alkil, amino, (C1-C4)alkilamino, [(C1-C4)alkil]2amino, fenil i -(C1-C4)alkil-fenil, gdje navedeni fenil je izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, cijano, (C1-C4)alkila i (C1-C4)alkoksi; ili R1 i R2, zajedno s atomom dušika na kojeg su vezani, tvore 3-, 4-, 5-, 6- ili 7-eročlani zasićeni heterocikl, gdje jedan atom ugljika može biti zamijenjen s N, O, S, SO ili SO2, te gdje navedeni zasićeni heterocikl je izborno supstituiran s jednom ili dvije skupine, koje se neovisno bira između hidroksi, halogena, =O, (C1-C4)alkila, -(C1-C4)alkil(C3-C6)cikloalkila, (C1-C4)alkoksi, hidroksi(C1-C4)alkila, (C1-C4)alkoksi(C1-C4)alkila, -SO2(C1-C4)alkila, -C(O)(C1-C4)alkila, [(C1-C4)alkil]2amino, amino, (C1-C4)alkilamino, -C(O)NH2, C(O)O(C1-C4)alkila i pirolidinona; svakog od R3 i R4 se neovisno bira između vodika, (C3-C6)cikloalkila i (C1-C4)alkila, gdje navedeni (C3-C6)cikloalkil i (C1-C4)alkil su izborno supstituirani s amino, (C1-C4)alkilamino, [(C1-C4)alkil]2amino ili (C3-C6)cikloalkilom, ili R3 i R4, zajedno s atomom dušika na kojeg su vezani, tvore 4-, 5-, 6- ili 7-eročlani zasićeni heterocikl, gdje jedan atom ugljika može biti zamijenjen s N ili O, te gdje navedeni zasićeni heterocikl je izborno supstituiran s (C1-C4)alkilom, [(C1-C4)alkil]2amino, amino, (C1-C4)alkilamino ili -C(O)(C1-C4)alkilom, a navedeni -C(O)(C1-C4)alkil je izborno supstituiran s metoksi ili

Claims (34)

1. Spoj formule (1): [image] ili njegova farmaceutski prihvatljiva sol i/ili solvat (uključujući hidrat), naznačen time što: supstituent formule -Z-R je u meta- ili para-položaju na fenilnoj skupini; X se bira između -CN, -CH2OH, -CH2-O-(C1-C4)alkila, -C(O)OH, -C(O)O(C1-C4)alkil, -CH2-NR1R2, -C(O)NR3R4, -CH2-O-het2, -CH2-het1 i het1, gdje skupina het1 u i -CH2-het1 i het1 je izborno supstituirana s jednim ili dva supstituenta, koje se neovisno bira između halogena, cijano, (C1-C4)alkila, -S-(C1-C4)alkila i (C1-C4)alkoksi; R1 je vodik ili (C1-C4)alkil, izborno supstituiran s (C3-C8)cikloalkilom; R2 se bira iz skupine koju čine: vodik, (C1-C6)alkil, izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između (C3-C6)cikloalkila, hidroksi, -S-(C1-C4)alkila, -O-(C1-C4)alkila, -SO2(C1-C4)alkila, -SO-(C1-C4)alkila, halogena, het1, amino, (C1-C4)alkilamino, [(C1-C4)alkil]2amino i fenila, gdje navedeni fenil je izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, hidroksi, cijano, (C1-C4)alkila, (C1-C4)alkoksi i (C3-C6)cikloalkila, het2, izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, cijano, (C1-C4)alkila, NH2 i (C1-C4)alkoksi, -SO2-R5, gdje R5 se bira iz skupine koju čine (C1-C4)alkil, amino, (C1-C4)alkilamino, [(C1-C4)alkil]2amino, fenil i -(C1-C4)alkil-fenil, gdje navedeni fenil je izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, cijano, (C1-C4)alkila i (C1-C4)alkoksi, i -C(O)-R6, gdje R6 se bira iz skupine koju čine (C1-C4)alkil, amino, (C1-C4)alkilamino, [(C1-C4)alkil]2amino, fenil i -(C1-C4)alkil-fenil, gdje navedeni fenil je izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, cijano, (C1-C4)alkila i (C1-C4)alkoksi; ili R1 i R2, zajedno s atomom dušika na kojeg su vezani, tvore 3-, 4-, 5-, 6- ili 7-eročlani zasićeni heterocikl, gdje jedan atom ugljika može biti zamijenjen s N, O, S, SO ili SO2, te gdje navedeni zasićeni heterocikl je izborno supstituiran s jednom ili dvije skupine, koje se neovisno bira između hidroksi, halogena, =O, (C1-C4)alkila, -(C1-C4)alkil(C3-C6)cikloalkila, (C1-C4)alkoksi, hidroksi(C1-C4)alkila, (C1-C4)alkoksi(C1-C4)alkila, -SO2(C1-C4)alkila, -C(O)(C1-C4)alkila, [(C1-C4)alkil]2amino, amino, (C1-C4)alkilamino, -C(O)NH2, C(O)O(C1-C4)alkila i pirolidinona; svakog od R3 i R4 se neovisno bira između vodika, (C3-C6)cikloalkila i (C1-C4)alkila, gdje navedeni (C3-C6)cikloalkil i (C1-C4)alkil su izborno supstituirani s amino, (C1-C4)alkilamino, [(C1-C4)alkil]2amino ili (C3-C6)cikloalkilom, ili R3 i R4, zajedno s atomom dušika na kojeg su vezani, tvore 4-, 5-, 6- ili 7-eročlani zasićeni heterocikl, gdje jedan atom ugljika može biti zamijenjen s N ili O, te gdje navedeni zasićeni heterocikl je izborno supstituiran s (C1-C4)alkilom, [(C1-C4)alkil]2amino, amino, (C1-C4)alkilamino ili -C(O)(C1-C4)alkilom, a navedeni -C(O)(C1-C4)alkil je izborno supstituiran s metoksi ili etoksi, Y se bira između CH2, CH(OH), O, C=O i N, gdje navedeni N je supstituiran s H, (C1-C4)alkilom, C(O)(C1-C4)alkilom ili (C1-C4)alkoksi(C1-C4)alkilom; Z se bira između O, S, SO i SO2; i m i p su cijeli brojevi, koji su neovisno 1, 2 ili 3, uz uvjet da m + p je jednako ili manje od 4, tako da prsten kojeg tvore: [image] je 4-, 5- ili 6-eročlani prsten; a R je bilo skupina formule: [image] gdje * predstavlja mjesto vezanja na Z, L je nerazgranati ili razgranati (C2-C6)alkilen, a svakog od R7 i R3 se neovisno bira između vodika, (C1-C6)alkila, (C3-C6)cikloalkila, hidroksi(C1-C6)alkila, ili R7 i R8, zajedno s atomom dušika na kojeg su vezani, tvore 4-, 5-, 6- ili 7-eročlani zasićeni heterocikl, gdje jedan atom ugljika je izborno zamijenjen s N, O, S, SO ili SO2, te gdje navedeni zasićeni heterocikl je izborno supstituiran s jednom ili dvije skupine, koje se neovisno bira između (C1-C4)alkila, (C1-C4)alkoksi, (C1-C4)alkoksi(C1-C4)alkila, hidroksi(C1-C4)alkila, hidroksi, C(O)O(C1-C4)alkila, -C(O)-(C1-C4)alkil-NH2, -C(O)NH2, halogena, amino, (C1-C4)alkilamino i [(C1-C4)alkil]2amino, ili R je skupina formule: [image] gdje * predstavlja mjesto vezanja na Z, prsten s dušikom je 4- do 7-eročlani zasićeni heterocikl, n je cijeli broj jednak 0, 1 ili 2, a R9 predstavlja supstituent, kojeg se bira između vodika, (C1-C4)alkil, hidroksi (C1-C6 alkil) i (C3-C6)cikloalkil; het1 se bira između monocikličkih ili bicikličkih heteroaromatskih skupina s 5 do 10 članova u prstenu, koje sadrže 1, 2, 3 ili 4 heteroatoma, koje se bira između dušika, kisika i sumpora, a het2 se bira između monocikličkih ili bicikličkih heteroaromatskih skupina s 5 do 10 članova u prstenu, koje sadrže 1, 2, 3 ili 4 heteroatoma, koje se bira između dušika, kisika i sumpora.
2. Spoj formule (1) u skladu s patentnim zahtjevom 1, naznačen time što X se bira između -CH2-NR1R2, -C(O)NR3R4, -CH2-het1 i het1, gdje het1 je izborno jednom ili dvaput supstituiran s (C1-C4)alkilom, gdje R1, R2, R3, R4 i het1 su definirani kao ranije, u patentnom zahtjevu 1.
3. Spoj formule (1) u skladu s patentnim zahtjevom 2, naznačen time što X je -CH2-het1 ili het1, gdje het1 se bira između 5- ili 6-eročlane monocikličke heteroaromatske skupine ili 9-eročlane bicikličke heteroaromatske skupine, gdje svaka heteroaromatska skupina sadrži 1 do 3 atoma dušika, ili 1 do 2 atoma dušika i 1 atom kisika, ili 1 atom dušika i 1 atom sumpora, a svaka heteroaromatska skupina je izborno jednom ili dvaput supstituirana s (C1-C4)alkilom.
4. Spoj formule (1) u skladu s patentnim zahtjevom 3, naznačen time što X je tiazolil, benzimidazolilmetil-, piridin oksazolil, imidazopiridinilmetil-, pirimidinil, imidazolil, imidazolilmetil- ili triazolilmetil-, gdje svaki od navedenih tiazolila, benzimidazolilmetila, piridinila, oksazolila, imidazopiridinilmetila, pirimidinila, imidazolila, imidazolilmetila i triazolilmetila je izborno supstituiran s jednom metilnom skupinom.
5. Spoj formule (1) u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što R1 je vodik, metil ili etil.
6. Spoj formule (1) u skladu s patentnim zahtjevom 1, patentni zahtjev 2 ili patentni zahtjev 5, naznačen time što R2 se bira iz skupine koju čine vodik, (C1-C6)alkil, izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između -S-(C1-C4)alkila, -O-(C1-C4)alkila, -SO2-(C1-C4)alkila i fenila, gdje navedeni fenil je izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, hidroksi, cijano, (C1-C4)alkila i (C1-C4)alkoksi, (C3-C6)cikloalkil, het2, izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, cijano, (C1-C4)alkila i (C1-C4)alkoksi, gdje het2 je definiran kao u patentnom zahtjevu 1, -SO2-R5, gdje R6 se bira iz skupine koju čine (C1-C4)alkil, [(C1-C4)alkil]2amino, fenil i -(C1-C4)alkil-fenil, gdje navedeni fenil je izborno supstituiran s 1 supstituentom, kojeg se neovisno bira između halogena i cijano i -C(O)-R6, gdje R6 se bira iz skupine koju čine (C1-C4)alkil, ((C1-C4)alkil]2amino, amino i -(C1-C4)alkil-fenil, gdje navedeni fenil je izborno supstituiran s jednim ili dva supstituenta, koje se neovisno bira između halogena, cijano, (C1-C4)alkila i (C1-C4)alkoksi.
7. Spoj formule (1) u skladu s patentnim zahtjevom 6, naznačen time što R2 se bira iz skupine koju čine (C1-C3)alkil, izborno supstituiran s -O-(C1-C3)alkilom, (C3-C5)cikloalkil, het2, gdje het2 se bira iz skupine koju čine 5- ili 6-eročlane monocikličke heteroaromatske skupine s 1 do 2 atoma dušika ili 1 atom dušika i 1 atom kisika ili 1 atom dušika i 1 atom sumpora, gdje je navedeni het2 izborno supstituiran s (C1-C4)alkilom, SO2-R5, gdje R6 je (C1-C4)alkil, te C(O)-R6, gdje R6 je (C1-C4)alkil.
8. Spoj formule (1) u skladu s patentnim zahtjevom 7, naznačen time što R2 je (C1-C3)alkil, izborno supstituiran s metoksi.
9. Spoj formule (1) u skladu s patentnim zahtjevom 7, naznačen time što R2 je het2, gdje het2 se bira iz skupine koju čine 5- ili 6-eročlane monocikličke heteroaromatske skupine s 1 ili 2 atoma dušika.
10. Spoj formule (1) u skladu s patentnim zahtjevom 9, naznačen time što R2 je piridazinilna skupina.
11. Spoj formule (1) u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što R1 i R2, zajedno s atomom dušika na kojeg su vezani, tvore 4-, 5-, 6- ili 7-eročlani zasićeni heterocikl, gdje jedan atom ugljika može biti zamijenjen s N, O, S, SO ili SO2, te gdje navedeni zasićeni heterocikl je izborno supstituiran s jednom ili dvije skupine, koje se neovisno bira između hidroksi, halogena, =O, (C1-C4)alkila, -(C1-C4)alkil(C3-C6)cikloalkila, (C1-C4)alkoksi, hidroksi(C1-C4)alkila, (C1-C4)alkoksi(C1-C4)alkila, -SO2(C1-C4)alkila, -C(O)(C1-C4)alkila, [(C1-C4)alkil]2amino, -C(O)NH2, C(O)O(C1-C4)alkila i pirolidinona.
12. Spoj formule (1) u skladu s patentnim zahtjevom 11, naznačen time što R1 i R2, zajedno s atomom dušika na kojeg su vezani, tvore morfolinilnu skupinu.
13. Spoj formule (1) u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što svakog od R3 i R4 se neovisno bira između vodika i (C1-C4)alkila, ili R3 i R4, zajedno s atomom dušika na kojeg su vezani, tvore 4-, 5- ili 6-eročlani zasićeni heterocikl, gdje jedan atom ugljika može biti zamijenjen s N ili O, te gdje navedeni zasićeni heterocikl je izborno supstituiran s (C1-C4)alkilom.
14. Spoj formule (1) u skladu s patentnim zahtjevom 13, naznačen time što R3 i R4 se neovisno bira između vodika, metila i etila, ili R3 i R4, zajedno s atomom dušika na kojeg su vezani, tvore pirolidinilni, piperidinilni, piperazinilni ili azetidinilni prsten, gdje svaki od pirolidinilnog, piperidinilnog, piperazinilnog i azetidinilnog prstena je izborno supstituiran metilom.
15. Spoj formule (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što Y se bira između CH2, CH(OH), O i C=O.
16. Spoj formule (1) u skladu s patentnim zahtjevom 15, naznačen time što Y je O.
17. Spoj formule (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što Z je O.
18. Spoj formule (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što i m i p su 2.
19. Spoj formule (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što R je skupina formule: [image] gdje * predstavlja mjesto vezanja na Z, L je (C2-C5)alkilen, a svakog od R7 i R8 se neovisno bira između vodika, (C1-C8)alkila, (C3-C6)cikloalkila, hidroksi(C1-C6)alkila, ili R7 i R8, zajedno s atomom dušika na kojeg su vezani, tvore 4-, 5-, 6- ili 7-eročlani zasićeni heterocikl, gdje jedan atom ugljika je izborno zamijenjen s N, O, S, SO ili SO2, te gdje navedeni zasićeni heterocikl je izborno supstituiran s jednom ili dvije skupine, koje se neovisno bira između (C1-C4)alkila, (C1-C4)alkoksi, (C1-C4)alkoksi(C1-C4)alkila, hidroksi(C1-C4)alkila, hidroksi, C(O)O(C1-C4)alkila, -C(O)-(C1-C4)alkil-NH2, -C(O)NH2 i halogena.
20. Spoj formule (1) u skladu s patentnim zahtjevom 19, naznačen time što R7 i R8, zajedno s atomom dušika na kojeg su vezani, tvore morfolinilnu ili oksazepanilnu skupinu.
21. Spoj formule (1) u skladu s patentnim zahtjevom 19, naznačen time što R7 i R8, zajedno s atomom dušika na kojeg su vezani, tvore 4-, 5- ili 6-eročlani zasićeni heterocikl, izborno supstituiran s jednom ili dvije (C1-C4)alkilne skupine.
22. Spoj formule (1) u skladu s patentnim zahtjevom 21, naznačen time što zasićeni heterocikl je pirolidinilna skupina, izborno supstituirana s jednom ili dvije metilne skupine.
23. Spoj formule (1) u skladu s patentnim zahtjevom 19, naznačen time što R7 i R8 su (C1-C3)alkili.
24. Spoj formule (1) u skladu s bilo kojim od patentnih zahtjeva 19 to 23, naznačen time što L je propilen.
25. Spoj formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 18, naznačen time što R je skupina formule: [image] gdje * predstavlja mjesto vezanja na Z, prsten s dušikom je 4- ili 6-eročlani zasićeni heterocikl, n je cijeli broj jednak 0 ili 1, a R9 predstavlja supstituent, kojeg se bira između vodika, (C1-C4)alkila i (C3-C5)cikloalkila.
26. Spoj formule (1) u skladu s patentnim zahtjevom 25, naznačen time što R9 je izopropil ili ciklobutil.
27. Spoj formule (1) u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između: N-{4-[4-(3-pirolidin-1-ilpropoksi)fenil]tetrahidropiran-4-ilmetil}metansulfonamida; {4-[4-(3-pirolidin-1-ilpropoksi)fenil]tetrahidropiran-4-ilmetil}uree; amida 4-[4-(3-pirolidin-1-ilpropoksi)fenil]tetrahidro-2H-piran-4-karboksilne kiseline; 4-{4-[(-1-izopropilpiperidin-4-il)oksi]fenil}tetrahidro-2H-piran-4-karboksamida; 4-{4-[(1-ciklobutilpiperidin-4-il)oksi]fenil}-tetrahidro-2H-piran-4-karboksamida; N-{[4-(4-{3-[(3R)-3-(dimetilamino)pirolidin-1-il]propoksi}fenil)tetrahidro-2H-piran-4-il]metil}-N-metilmetansulfonamida; i N4-{4-[4-(3-pirolidin-1-ilpropoksi)fenil]tetrahidropiran-4-ilmetil}piridin-3,4-diamina.
28. Farmaceutski pripravak, naznačen time što sadrži spoj formule (1), ili njegovu farmaceutski prihvatljivu sol i/ili solvat, u skladu s bilo kojim od prethodnih patentnih zahtjeva, zajedno s farmaceutski prihvatljivom pomoćnom tvari.
29. Spoj formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol i/ili solvat, naznačen time što je namijenjen upotrebi kao medikament.
30. Upotreba spoja formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive sol i/ili solvata, naznačena time što navedeni spoj je namijenjen proizvodnji medikamenta za liječenje poremećaja spavanja, migrene, diskinezije, anksioznosti uzrokovane stresom, psihotičnih poremećaja, epilepsije, bolesti spoznajne deficijencije, depresije, poremećaja raspoloženja, shizofrenije, anksioznih poremećaja, poremećaja nedostatka pažljivosti s hiperaktivnošću (ADHD), psihotičnih poremećaja, pretilosti, vrtoglavice, vertiga, epilepsije, bolesti kretanja, upalnih bolesti, sindroma respiratornog distresa kod odraslih, akutnog sindroma respiratornog distresa, bronhitisa, kroničnog bronhitisa, kronične opstruktivne plućne bolesti, cistične fibroze, astme, emfizema, rinitisa, kroničnog sinusitisa, alergije, alergijskih reakcija dišnih puteva, alergijskog rinitisa, virusnog rinitisa, nealergijskog rinitisa, nesezonskog i sezonskog rinitisa, začepljenja nosa, alergijske kongestije, spolne disfunkcije kod muškaraca ili spolne disfunkcije kod žena.
31. Upotreba spoja formule (1) u skladu s patentnim zahtjevom 30, naznačena time što bolest spoznajne deficijencije je Alzheimerova bolest ili blagi kognitivni poremećaj.
32. Kombinacija spoja formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 27, naznačena time što je to kombinacija s drugim farmakološki aktivnim sredstvom.
33. Kombinacija u skladu s patentnim zahtjevom 32, naznačena time što drugo farmakološki aktivno sredstvo je antagonist histaminskog receptora H1.
34. Spoj formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol i/ili solvat, naznačen time što je namijenjen upotrebi u liječenju bolesti, poremećaja i stanja u skladu s patentnim zahtjevima 30 i 31.
HR20100469T 2004-05-07 2010-08-27 3- ili 4-monosupstituirani fenolski i tiofenolski derivati, korisni kao h<sub>3</sub> ligandi HRP20100469T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04291187A EP1593679A1 (en) 2004-05-07 2004-05-07 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands
GB0504564A GB0504564D0 (en) 2005-03-04 2005-03-04 New compounds
PCT/IB2005/001114 WO2005108384A1 (en) 2004-05-07 2005-04-19 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands

Publications (1)

Publication Number Publication Date
HRP20100469T1 true HRP20100469T1 (hr) 2010-10-31

Family

ID=34964551

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100469T HRP20100469T1 (hr) 2004-05-07 2010-08-27 3- ili 4-monosupstituirani fenolski i tiofenolski derivati, korisni kao h<sub>3</sub> ligandi

Country Status (37)

Country Link
EP (1) EP1747210B1 (hr)
JP (2) JP4173191B2 (hr)
KR (1) KR100843848B1 (hr)
CN (1) CN1950351B (hr)
AP (1) AP2353A (hr)
AR (1) AR048939A1 (hr)
AT (1) ATE472540T1 (hr)
AU (1) AU2005240846B2 (hr)
BR (1) BRPI0510664B8 (hr)
CA (1) CA2565852C (hr)
CR (1) CR8729A (hr)
CY (1) CY1110735T1 (hr)
DE (1) DE602005022062D1 (hr)
DK (1) DK1747210T3 (hr)
EA (1) EA011161B1 (hr)
EC (1) ECSP066975A (hr)
ES (1) ES2346665T3 (hr)
GE (1) GEP20094826B (hr)
GT (1) GT200500107A (hr)
HK (1) HK1100823A1 (hr)
HR (1) HRP20100469T1 (hr)
IL (1) IL178433A (hr)
MA (1) MA28634B1 (hr)
MX (1) MXPA06012819A (hr)
MY (1) MY144634A (hr)
NL (1) NL1028968C2 (hr)
NZ (1) NZ550769A (hr)
PA (1) PA8632201A1 (hr)
PE (1) PE20060237A1 (hr)
PL (1) PL1747210T3 (hr)
PT (1) PT1747210E (hr)
RS (1) RS51403B (hr)
SI (1) SI1747210T1 (hr)
SV (1) SV2006002107A (hr)
TW (2) TWI346549B (hr)
UY (1) UY28883A1 (hr)
WO (1) WO2005108384A1 (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
NZ548212A (en) 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
JP2006213674A (ja) * 2005-02-07 2006-08-17 Ube Ind Ltd ４−ホルミルテトラヒドロピラン化合物の製法
EP1904066B1 (en) 2005-07-06 2018-05-23 Sunovion Pharmaceuticals Inc. COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, for treating MENOPAUSE, perimenopause AND COGNITIVE DISORDERS
WO2007045989A1 (en) * 2005-10-20 2007-04-26 Pfizer Limited Pyridyl derivatives useful as h3 ligands
KR101381768B1 (ko) 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제
JP5432526B2 (ja) 2006-01-06 2014-03-05 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害剤としてのシクロアルキルアミン
AU2007233041B2 (en) 2006-03-31 2013-05-02 Sepracor Inc. Preparation of chiral amides and amines
TW200806627A (en) 2006-04-11 2008-02-01 Novartis Ag Organic compounds
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AU2007260836B2 (en) 2006-06-23 2012-11-15 Abbvie Bahamas Ltd. Cyclopropyl amine derivatives as histamin H3 receptor modulators
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
BRPI0718874A2 (pt) * 2006-12-22 2015-06-23 Novartis Ag Compostos orgânicos
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
NZ580429A (en) 2007-05-31 2012-04-27 Sepracor Inc Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
TW201039822A (en) 2009-02-06 2010-11-16 Taisho Pharmaceutical Co Ltd Dihydroquinolinone derivatives
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
MX337469B (es) * 2011-10-26 2016-03-02 Pfizer Ltd Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.
WO2014095534A1 (en) * 2012-12-19 2014-06-26 Basf Se New substituted triazoles and imidazoles and their use as fungicides
DK3309150T3 (da) * 2013-01-09 2021-08-30 Arena Pharm Inc (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propansyre som histamin-h3-receptormodulatorer til behandlingen af kognitive lidelser
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
NZ733825A (en) 2014-12-18 2022-02-25 Genzyme Corp Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
CN113336715B (zh) * 2021-08-04 2021-11-23 山东海利尔化工有限公司 一种含二氧戊环的三唑类化合物及其中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3024836A1 (de) * 1980-07-01 1982-01-28 A. Nattermann & Cie GmbH, 5000 Köln (3-alkylamino-2-hydroxy-propoxy)-benzylnitrile, verfahren zu deren herstellung und diese als wirkstof enthaltende arzneimittel
DK368687A (da) * 1986-11-21 1988-05-22 Cheminova As Aminoalkylerede hydroxyforbindelser og deres anvendelse som fungicider
PT1301480E (pt) * 2000-07-13 2007-11-29 Abbott Lab Pirrolidinas 1,3-di-substituídas e 1,3,3-tri-substituídas úteis como ligandos do receptor de histamina-3 e suas aplicações terapêuticas
AU8112101A (en) * 2000-08-08 2002-02-18 Ortho Mcneil Pharm Inc Non-imidazole aryloxypiperidines
AU2002254114A1 (en) * 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses

Also Published As

Publication number Publication date
KR20060133091A (ko) 2006-12-22
EP1747210B1 (en) 2010-06-30
CY1110735T1 (el) 2015-06-10
DE602005022062D1 (de) 2010-08-12
NZ550769A (en) 2010-06-25
TWI346549B (en) 2011-08-11
SI1747210T1 (sl) 2010-09-30
MXPA06012819A (es) 2007-01-26
CA2565852C (en) 2010-08-10
AU2005240846A1 (en) 2005-11-17
JP4173191B2 (ja) 2008-10-29
ES2346665T3 (es) 2010-10-19
CR8729A (es) 2006-11-30
MA28634B1 (fr) 2007-06-01
BRPI0510664A (pt) 2007-12-04
PE20060237A1 (es) 2006-04-01
AR048939A1 (es) 2006-06-14
JP2008050365A (ja) 2008-03-06
AU2005240846B2 (en) 2011-08-25
RS51403B (en) 2011-02-28
EA200601868A1 (ru) 2007-04-27
SV2006002107A (es) 2006-06-26
AP2006003772A0 (en) 2006-10-31
HK1100823A1 (en) 2007-09-28
NL1028968A1 (nl) 2005-11-08
DK1747210T3 (da) 2010-09-27
PT1747210E (pt) 2010-08-31
WO2005108384A1 (en) 2005-11-17
MY144634A (en) 2011-10-14
CN1950351A (zh) 2007-04-18
AP2353A (en) 2012-02-16
IL178433A (en) 2011-12-29
EP1747210A1 (en) 2007-01-31
TW200815412A (en) 2008-04-01
BRPI0510664B8 (pt) 2021-05-25
TW200607494A (en) 2006-03-01
IL178433A0 (en) 2007-02-11
BRPI0510664B1 (pt) 2020-04-07
PL1747210T3 (pl) 2010-11-30
ECSP066975A (es) 2006-12-29
GT200500107A (es) 2006-01-10
KR100843848B1 (ko) 2008-07-03
CN1950351B (zh) 2012-01-18
GEP20094826B (en) 2009-11-10
ATE472540T1 (de) 2010-07-15
CA2565852A1 (en) 2005-11-17
EA011161B1 (ru) 2009-02-27
NL1028968C2 (nl) 2006-04-03
UY28883A1 (es) 2005-12-30
JP2007536365A (ja) 2007-12-13
PA8632201A1 (es) 2006-09-22

Similar Documents

Publication Publication Date Title
HRP20100469T1 (hr) 3- ili 4-monosupstituirani fenolski i tiofenolski derivati, korisni kao h&lt;sub&gt;3&lt;/sub&gt; ligandi
JP2008050365A5 (hr)
ES2375111T3 (es) Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-quinasa y su uso en el tratamiento de c�?ncer.
RU2386630C2 (ru) Соединения и композиции в качестве ингибиторов протеинтирозинкиназы
US20130023532A1 (en) Indazolyl-pyrimidines as kinase inhibitors
ES2623229T3 (es) Nuevos antagonistas de hepcidina de sulfonaminoquinolina.
HRP20140061T1 (hr) Antagonisti histaminskog receptora h3
ES2358579T3 (es) Nuevas indazolcarboxamidas y su uso.
CA2564201A1 (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
RU2357952C2 (ru) Новые эфиры гидроксамовых кислот и их фармацевтическое применение
AR054127A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
JP2012502986A5 (hr)
CN103842357A (zh) 作为类香草素受体配体的被取代的、含有杂芳环吡唑的羧酰胺和脲衍生物
US20130023534A1 (en) Pyrazolyl-pyrimidines as kinase inhibitors
RU2009140465A (ru) Имидазохинолины с иммуномодулирующими свойствами
JP2008534511A5 (hr)
ES2499028T3 (es) Derivados de anilino-pirimidina sustituidos con sulfoximina como inhibidores de CDK, su preparación y uso como medicamentos
JP2005509024A5 (hr)
JP2013502429A5 (hr)
JP2011506333A (ja) 新規ｓＥＨ阻害剤およびその使用
JP2013531055A5 (hr)
US9238644B2 (en) VEGFR3 inhibitors
JP2006525990A5 (hr)
JP2011519845A5 (hr)
JP2016522240A (ja) ＲＯＲｃモジュレーターとしてのアリールスルタム誘導体